Related references
Note: Only part of the references are listed.Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension
Roberto Fogari et al.
HYPERTENSION RESEARCH (2011)
Different Effects of Aliskiren and Losartan on Fibrinolysis and Insulin Sensitivity in Hypertensive Patients with Metabolic Syndrome
R. Fogari et al.
HORMONE AND METABOLIC RESEARCH (2010)
Angiotensin-Converting Enzyme Inhibition Augments Coronary Release of Tissue Plasminogen Activator in Women But Not in Men
Tetsuya Matsumoto et al.
HYPERTENSION (2010)
Ablation of Angiotensin IV Receptor Attenuates Hypofibrinolysis via PAI-1 Downregulation and Reduces Occlusive Arterial Thrombosis
Yasushi Numaguchi et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Current concepts: renin inhibition in the treatment of hypertension
Alan H. Gradman et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension
Ling Liu et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency
N. J. Brown et al.
KIDNEY INTERNATIONAL (2007)
Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease
Carlos M. Ferrario et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
SM Grundy et al.
CIRCULATION (2005)
Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension
T Skurk et al.
DIABETES OBESITY & METABOLISM (2004)
Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients
R Fogari et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin
M Pretorius et al.
CIRCULATION (2003)
Effects of losartan and delapril on the fibrinolytic system in patients with mild to moderate hypertension
S Paterna et al.
CLINICAL DRUG INVESTIGATION (2003)
ACE inhibition versus angiotensin type 1 receptor antagonism - Differential effects on PAM over time
NJ Brown et al.
HYPERTENSION (2002)
Effects of angiotensins II and IV on blood pressure, renal function, and PAI-1 expression in the heart and kidney of the rat
CT Abrahamsen et al.
PHARMACOLOGY (2002)
Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients
R Fogari et al.
AMERICAN JOURNAL OF HYPERTENSION (2002)
Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease
Y Shibasaki et al.
NEPHRON (2002)
Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women
R Fogari et al.
AMERICAN JOURNAL OF HYPERTENSION (2001)
Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture
T Skurk et al.
HYPERTENSION (2001)
Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: Effects of angiotensin-converting enzyme inhibitors
K Minai et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2001)
Effects of four angiotensin II-receptor antagonists on fibrinolysis in postmenopausal women with hypertension
R Fogari et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2001)
Fibrinolytic function in diuretic-induced volume depletion
K Lottermoser et al.
AMERICAN JOURNAL OF HYPERTENSION (2000)
Association of blood pressure with fibrinolytic potential in the Framingham Offspring population
KA Poli et al.
CIRCULATION (2000)
Share Paper
